Eleven Biotherapeutics Gets Rocking As Next Generation Biologics Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
Proceeds from a $35 million Series A financing, led by Flagship Ventures and Third Rock Ventures, will be used to build R&D and business development teams.